Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.

Tirzepatide

Animal replicated

FDA-approvedPeptide

RouteInjectableFDA-approved

Quick take

What it is: Tirzepatide is a synthetic 39-amino acid dual agonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R), developed by Eli Lilly and Company. Single-chain peptide with C20 fatty diacid lipidation enabling once-weekly subcutaneous dosing. FDA-approved as Mounjaro (doses 2.5-15 mg; T2D glycemic control, 2022) and Zepbound (doses 2.5-15 mg; chronic weight management, 2023; additional CV risk reduction indication in overweight/obese with CVD, 2024). It is the most efficacious approved obesity pharmacotherapy in history at its highest dose.
Why people use it: The Most Efficacious Approved Obesity Drug in Human History. SURMOUNT-1: -22.5% at 72 Weeks. SURMOUNT-5 Head-to-Head vs Semaglutide (NEJM 2025): 20.2% vs 13.7% — 47% Greater Relative Weight Loss. GI Discontinuation Lower Than Semaglutide. The GIP Receptor Rehabilitation Story. The Weight Rebound Data. SURMOUNT-4: >25% Regain in Most Within 1 Year of Stopping. Compounded Tirzepatide FDA Status After December 2024 Shortage Removal. SURPASS-CVOT: The CV Question Semaglutide Already Answered.
What the evidence supports: SURMOUNT-4 (JAMA 2023) and the post-hoc JAMA Internal Medicine analysis (February 2026) together provide the most current and comprehensive tirzepatide withdrawal data. The core finding: among participants who had achieved ≥10% weight reduction on 36 weeks of tirzepatide and then stopped, the mean weight regain was 14% over the subsequent 52 weeks. More importantly, the JAMA Int Med post-hoc analysis showed that >25% of initial weight loss was regained in most patients within 1 year — and those who regained the most weight had the greatest reversal of cardiometabolic benefits (HbA1c rose, blood pressure increased, lipids worsened proportionally to weight regained). The editorial accompanying the post-hoc analysis made the clinical point explicitly: 'There is a common misconception that patients can stop antiobesity medications when they reach their goal weight and maintain the weight that they lost and the cardiometabolic benefits they achieved.' The data contradicts this misconception directly.

If you only read one thing

Tirzepatide is now the most efficacious approved obesity pharmacotherapy in history, confirmed by the SURMOUNT-5 head-to-head against semaglutide published in the NEJM in 2025: -20.2% vs -13.7% at 72 weeks — 47% greater relative weight loss from the direct comparison. The compound that was originally dismissed as redundant with semaglutide (both GLP-1 agonists) has comprehensively outperformed it. And the weight rebound data tells the same story as semaglutide: SURMOUNT-4 shows >25% weight regain within 1 year of stopping. The two defining questions for tirzepatide as of mid-2026: (1) Will SURPASS-CVOT confirm cardiovascular outcome benefit comparable to semaglutide's SELECT trial? Semaglutide's 20% MACE reduction is its most important clinical differentiation; tirzepatide's cardiovascular outcomes evidence is pending. (2) What happens as CagriSema (-22.7% REDEFINE 1) and potentially eloralintide approach approval — does tirzepatide remain best-in-class for weight loss? The competitive landscape is closing in.

Overview

Tirzepatide is the most efficacious approved obesity drug as of mid-2026. SURMOUNT-5 confirmed it head-to-head. The weight rebound challenge is identical to semaglutide. The cardiovascular outcomes story is still being written.

The honest summary: tirzepatide's efficacy advantage over semaglutide is real, substantial, and now head-to-head confirmed in a major NEJM publication. -20.2% vs -13.7% at 72 weeks; 47% greater relative weight loss; better GI tolerability at maximum dose. For the patient whose primary goal is maximum weight loss achievable with a once-weekly approved drug, tirzepatide is the current best option. The weight rebound data is equally clear: >25% of weight loss returns within 1 year of stopping for most patients, cardiometabolic benefits reverse with regain, and the chronic disease framing is mandatory for honest patient counseling. The cardiovascular outcomes gap — SELECT exists for semaglutide, SURPASS-CVOT is pending for tirzepatide — is the most important current evidence asymmetry between the two drugs. In the pipeline, CagriSema (-22.7% REDEFINE 1) and eloralintide (Phase 3 starting) are closing the efficacy gap; tirzepatide's window as the uncontested most-efficacious option is finite but real in 2026.

Properties

✓ FDA-approvedNot injectable

Evidence

CAnimal replicated

The Core Efficacy Numbers

SURMOUNT-1 (NEJM 2022; Jastreboff et al.): n=2,539; 72 weeks; obesity without T2D; -20.9% (10 mg), -22.5% (15 mg) vs -2.4% placebo. 91% of participants on 15 mg achieved ≥5% weight loss; 57% achieved ≥20% weight loss. SURMOUNT-5 (NEJM 2025; first head-to-head vs semaglutide): n=751; 72 weeks; maximum tolerated dose; tirzepatide -20.2% vs semaglutide -13.7%; 47% greater relative weight loss; GI discontinuation tirzepatide 2.7% vs semaglutide 5.6%. SURPASS-2 (NEJM 2021): head-to-head vs semaglutide 1 mg in T2D; tirzepatide 15 mg = -2.46% HbA1c vs -1.86% for semaglutide.

Mounjaro vs Zepbound

Both are tirzepatide — the same molecule from Eli Lilly. Mounjaro: approved May 2022 for T2D; doses 2.5-15 mg; standard dose escalation every 4 weeks. Zepbound: approved November 2023 for obesity (BMI ≥30 or ≥27 + ≥1 comorbidity); same doses; cardiovascular risk reduction indication added 2024 (like Wegovy). Same pen device, different label, different indication, different insurance coverage paths. Using Mounjaro off-label for obesity = same molecule at same doses as Zepbound, different indication, different coverage.

The GIP Receptor Story

GIP (glucose-dependent insulinotropic polypeptide) was historically considered a poor drug target for metabolic disease — GIP's insulinotropic response is impaired in T2D ('incretin effect' reduction), and some researchers argued GIP receptor agonism might worsen insulin resistance. Tirzepatide's extraordinary efficacy rehabilitated the GIP receptor as a metabolic target. The key insight: GIPR agonism at pharmacological doses (not physiological) produces beneficial effects in adipose tissue (reducing fat deposition, increasing energy expenditure), brain (reducing appetite via a distinct pathway from GLP-1R), and pancreas (improving beta cell function). Crucially, the GIP and GLP-1 mechanisms appear synergistic rather than simply additive at the receptor level.

Weight Rebound and Compounded Status

SURMOUNT-4 (JAMA 2023; post-hoc JAMA Int Med Feb 2026): withdrawal after 36 weeks → mean 14% weight regain over 52 weeks; >25% regain in most patients within 1 year; cardiometabolic benefits reversed. Same chronic disease framing as semaglutide. Compounded tirzepatide: FDA removed tirzepatide from shortage list December 2024; compounders directed to wind down by March 2025; legal challenges ongoing; documented quality issues (incorrect potency, contamination, mislabeled compounds). SURPASS-CVOT: cardiovascular outcomes trial vs dulaglutide; results expected 2025-2026; will determine whether tirzepatide matches semaglutide's SELECT MACE benefit.

Structure

Molecular profile

MW · —

Half-life · —

Class · Peptide

Route · —

Tirzepatide's development forced a fundamental reassessment of GIP receptor biology. For decades the GIP receptor was considered a dead end. Tirzepatide proved the conventional wisdom wrong — and produced the highest efficacy numbers in obesity pharmacotherapy history in the process.

GIP (glucose-dependent insulinotropic polypeptide) is an incretin hormone secreted by K-cells in the small intestine in response to food intake. Like GLP-1, it stimulates glucose-dependent insulin secretion from pancreatic beta cells. The critical difference from GLP-1: in type 2 diabetes, the insulinotropic response to GIP is severely impaired — this is part of what's called the 'reduced incretin effect' in T2D. Because GIP's primary known action (insulin stimulation) was impaired in the disease state being treated, drug developers largely passed on GIP receptor agonism as a therapeutic strategy. GLP-1 maintained its insulinotropic response in T2D; GIP did not. The GLP-1 agonist class (liraglutide, semaglutide) was built on this foundation.

Eli Lilly's tirzepatide program challenged this assumption at multiple levels. In adipose tissue, GIPR activation produces distinct effects from pancreatic GIPR: it promotes energy storage efficiency, affects fat cell metabolism, and modulates adipokine secretion. In the brain, GIPR is expressed in hypothalamic appetite circuits — but distinct from GLP-1R circuits, suggesting independent appetite suppression pathways. In the pancreas, GIPR on beta cells has positive effects on beta cell mass and survival even when its acute insulinotropic response is attenuated. The key pharmacological insight that Lilly's program exploited: at pharmacological doses with dual agonism, the GIP receptor's beneficial adipose tissue and central nervous system effects are pharmacologically accessible even when its pancreatic incretin effect is impaired. The GIP component adds to GLP-1's mechanism rather than substituting for it — producing synergy that generates weight loss substantially greater than either receptor agonism alone.

Tirzepatide received FDA approval as Mounjaro for T2D in May 2022, as Zepbound for obesity in November 2023, and an additional Zepbound cardiovascular risk reduction indication in 2024. It is available in doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg — the most granular dose escalation ladder of any weekly GLP-1 class drug, designed to improve GI tolerability through slower titration.

THE CENTRAL TENSION

Tirzepatide has the most granular dose escalation of any weekly GLP-1 class drug — six dose levels compared to semaglutide's four-step Wegovy escalation. The design rationale: slower titration reduces GI adverse events during the escalation phase where they are most common. Standard escalation: 2.5 mg/week for 4 weeks → 5 mg/week for 4 weeks → 7.5 mg/week for 4 weeks → 10 mg/week for 4 weeks → 12.5 mg/week for 4 weeks → 15 mg/week maintenance. Total 20 weeks to reach maximum dose vs 16 weeks for Wegovy. Some patients settle at lower maintenance doses (5-10 mg) if GI tolerability is a concern; SURMOUNT-5 used maximum tolerated dose (10 or 15 mg) which explains the different efficacy number from SURMOUNT-1's prescribed-dose 15 mg comparison.

Mounjaro and Zepbound are the same molecule (tirzepatide) from Eli Lilly in the same doses using the same injection device. The differences are label, indication, and insurance coverage: Mounjaro is approved for T2D; Zepbound is approved for obesity and cardiovascular risk reduction. A physician can prescribe either for off-label use, but insurance coverage typically requires the matching indication. Mounjaro for T2D patients needing glycemic control and weight management; Zepbound for obesity patients without T2D. The community frequently uses the terms interchangeably — correctly so pharmacologically, incorrectly so from a regulatory/coverage standpoint.

THE GI TOLERABILITY ADVANTAGE — WHAT SURMOUNT-5 REVEALED

One of the most underreported findings from SURMOUNT-5: GI adverse events causing treatment discontinuation were lower with tirzepatide (2.7%) than with semaglutide (5.6%) at maximum tolerated doses. This is surprising given tirzepatide's higher weight loss — one might expect more GI burden with a more efficacious drug. The explanation may relate to the GIP component: GIPR agonism in the GI tract may have different (or moderating) effects on nausea/vomiting signaling than GLP-1R agonism alone. Whether this represents a genuine tolerability advantage or a dose-titration artifact (more patients on tirzepatide tolerated their maximum dose) requires further mechanistic investigation. The clinical implication: in practice, patients may find tirzepatide's GI profile more manageable than semaglutide's at full therapeutic doses.

Tirzepatide's GLP-1R component is mechanistically identical to semaglutide's GLP-1R activation: appetite suppression via hypothalamic and brainstem GLP-1R; glucose-dependent insulin secretion and glucagon suppression at the pancreas; gastric emptying delay; reduced food intake. The same weight loss, glycemic control, and cardiovascular-relevant anti-inflammatory effects documented for semaglutide are expected from tirzepatide's GLP-1R component. This is the foundation.

Tirzepatide's GIPR component adds pharmacological effects that are absent from GLP-1 monotherapy. In adipose tissue: GIPR activation on adipocytes modulates lipid storage and energy expenditure; tirzepatide produces greater reductions in visceral fat (the metabolically dangerous fat depot) compared to GLP-1 monotherapy at equivalent weight loss — suggesting direct GIPR effects on fat distribution beyond the weight loss magnitude. In the CNS: GIPR is expressed in the hypothalamus and brainstem in distinct circuits from GLP-1R; pharmacological GIPR agonism reduces food intake and appetite through pathways that are additive to GLP-1R-mediated satiety. This CNS dual receptor engagement is the primary pharmacological explanation for tirzepatide's greater weight loss vs semaglutide. In pancreatic beta cells: GIPR activation improves beta cell function and mass preservation even when the acute incretin response is attenuated — relevant for T2D treatment durability. In bone: GIPR signaling has documented effects on bone density; tirzepatide's bone safety data shows no significant bone loss at standard doses.

The most pharmacologically interesting feature of tirzepatide is that its weight loss efficacy appears to exceed what would be expected from adding GLP-1R and GIPR effects independently. The SURMOUNT-5 head-to-head result (-20.2% vs semaglutide's -13.7% at the same duration) represents a 6.5 percentage point absolute advantage and a 47% relative advantage. If the GIP effect were simply additive to GLP-1, the mechanistic prediction would be more modest. The current hypothesis: GIP and GLP-1 receptor signaling in the hypothalamus and brainstem interact synergistically — dual receptor engagement produces circuit-level effects that amplify appetite suppression beyond what either receptor produces alone. This synergy at the neural circuit level is the most important unexplained mechanistic question in tirzepatide pharmacology.

Tirzepatide has one of the largest and most rigorous clinical trial programs in metabolic pharmacotherapy — second only to semaglutide in human evidence volume. The SURMOUNT-5 head-to-head vs semaglutide is the most important single obesity pharmacotherapy trial published in 2025.

Jastreboff AM, et al. (2022) [1]. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 387(3):205-216. PMID 35658024. Design: Phase 3, randomized, double-blind, placebo-controlled; n=2,539; 72 weeks; adults with obesity (BMI ≥30) or overweight (BMI ≥27) + ≥1 comorbidity, without T2D. Doses: 5 mg, 10 mg, 15 mg weekly vs placebo. PRIMARY RESULTS: Mean weight loss at 72 weeks: 5 mg = -15.0%; 10 mg = -19.5%; 15 mg = -22.5% vs -2.4% placebo. At 15 mg: 91% achieved ≥5% weight loss; 57% achieved ≥20% weight loss; 36% achieved ≥25% weight loss. Absolute weight loss: mean -22.5 kg at 15 mg. The -22.5% figure was the highest weight loss number produced by any pharmacotherapy in a Phase 3 trial at the time of publication. This trial established tirzepatide as the new efficacy standard. Grade A: large Phase 3 DBRCT; validated endpoint; replicated in subsequent SURMOUNT trials.

Frías JP, et al. (2021) [5]. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 385(6):503-515. Design: Phase 3, open-label; n=1,879; T2D; tirzepatide 5/10/15 mg vs semaglutide 1 mg. HbA1c reduction: tirzepatide 15 mg = -2.46% vs semaglutide 1 mg = -1.86% (p<0.001). Weight loss: tirzepatide 15 mg = -12.7 kg vs semaglutide -6.2 kg. First head-to-head confirmation of tirzepatide superiority over semaglutide in T2D. Note: semaglutide 1 mg (Ozempic T2D dose) vs the full Wegovy 2.4 mg obesity dose is not head-to-head — SURMOUNT-5 corrected this.

Aronne LJ, et al. (2025) [4]. Tirzepatide versus Semaglutide for Obesity. New England Journal of Medicine. Published 2025. NCT05822830. Design: Phase 3b, open-label, randomized; n=751 adults with obesity or overweight + ≥1 comorbidity without T2D; tirzepatide maximum tolerated dose (10 or 15 mg) vs semaglutide maximum tolerated dose (1.7 or 2.4 mg); 72 weeks. PRIMARY ENDPOINT: mean body weight change at 72 weeks. RESULTS: Tirzepatide = -20.2% vs semaglutide = -13.7% (estimated treatment difference: -6.5 percentage points; 95% CI: -7.5 to -5.4; p<0.001). 47% greater relative weight loss. All 5 key secondary endpoints met by tirzepatide. Waist circumference: tirzepatide -18.4 cm vs semaglutide -13.0 cm. GI discontinuation: tirzepatide 2.7% vs semaglutide 5.6% — tirzepatide was better tolerated at maximum dose. Women: greater weight loss than men in both groups; tirzepatide women -23.8% vs semaglutide women -18.0%. This is the definitive head-to-head. It was open-label (not blinded) — the main limitation noted by commentators, as blinding is impossible when drug effects are clearly different. Grade A: large Phase 3b DBRCT design; NEJM publication; confirmatory of topline December 2024 announcement.

Aronne LJ, et al. (2023) [2]. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity. JAMA. 330(23):2247-2256. Post-hoc analysis: Horn DB, et al. JAMA Internal Medicine. Published online November 24, 2025; print February 1, 2026. 186(2):157-167. Design: n=670 adults who achieved ≥10% weight reduction on 36-week tirzepatide treatment; randomized 1:1 to continue tirzepatide MTD vs switch to placebo for 52 additional weeks. Results (continuation): additional -6.7% weight loss; total -26% from study entry. Results (withdrawal): mean +14% weight regain over 52 weeks. Post-hoc (JAMA Int Med 2026): >25% weight regain in most participants within 1 year of stopping; cardiometabolic benefits (HbA1c, blood pressure, lipids) reversed proportional to weight regained. The SURMOUNT-4 data confirms the same chronic disease framing as semaglutide — tirzepatide effectively manages obesity during treatment; the underlying condition reasserts itself when treatment stops.

Wadden TA, et al. (2023). Randomized Trial of Tirzepatide for Weight Loss in Overweight Adults After Intensive Lifestyle Intervention. New England Journal of Medicine. Design: n=806; lead-in intensive lifestyle intervention (mean -6.9% weight loss); then randomized to tirzepatide 10/15 mg vs placebo for 72 weeks. Total weight loss from study start: tirzepatide -26.6% vs placebo -3.1%. This study is significant for demonstrating that tirzepatide's weight loss is additive to lifestyle intervention — the two approaches are complementary, not competing.

Packer M, et al. (2024) [6]. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine. SUMMIT trial: n=731; obesity + HFpEF; tirzepatide vs placebo; primary outcome: Kansas City Cardiomyopathy Questionnaire (KCCQ) score + 6-minute walk test composite. Results: statistically significant improvement in both HF symptoms and exercise capacity. First trial showing pharmacotherapy improves functional outcomes in HFpEF. Published alongside the SELECT semaglutide CV data in NEJM — establishing the obesity-HF connection for GLP-1 class drugs.

Trial

Indication

Key Result

Grade

Published

SURMOUNT-1 (NEJM 2022)

Obesity without T2D

15 mg: -22.5% WL at 72wks vs -2.4% placebo; 57% ≥20% WL

NEJM 387:205 (2022)

SURMOUNT-2 (Lancet 2023)

Obesity + T2D

15 mg: -17.8% WL at 72wks vs -3.2% placebo; HbA1c -2.1%

Lancet 402:1343 (2023)

SURMOUNT-3 (NEJM 2023)

Obesity post-lifestyle intervention

Total WL -26.6% vs -3.1% placebo from study start

NEJM 388:2452 (2023)

SURMOUNT-4 (JAMA 2023; JAMA Int Med 2026)

Obesity — withdrawal study

Withdrawal: +14% regain; >25% regain in most within 1yr; CV benefits reversed

JAMA 330:2247 (2023); JAMA IM 186:157 (2026)

SURMOUNT-5 (NEJM 2025)

Head-to-head vs semaglutide 2.4mg

Tirzepatide -20.2% vs semaglutide -13.7%; 47% greater RWL; GI DC 2.7% vs 5.6%

NEJM 2025 (NCT05822830)

SURPASS-2 (NEJM 2021)

T2D vs semaglutide 1mg

Tirzepatide -2.46% HbA1c vs semaglutide -1.86%; WL -12.7kg vs -6.2kg

NEJM 385:503 (2021)

SUMMIT (NEJM 2024)

Obesity + HFpEF

Significant KCCQ + 6MWT improvement; first pharmacotherapy showing HFpEF benefit

NEJM 2024

SURPASS-CVOT

T2D + CVD vs dulaglutide

CV outcomes trial ongoing; results expected 2025-2026

Pending

Ongoing

SURMOUNT-5 settled the efficacy comparison. The remaining questions are cardiovascular outcomes and disease management strategy.

Feature

Tirzepatide (Zepbound/Mounjaro)

Semaglutide (Wegovy/Ozempic)

Mechanism

GLP-1R + GIPR dual agonist

GLP-1R agonist only

Phase 3 peak WL (obesity)

−22.5% (SURMOUNT-1, 15 mg, 72 wks)

−14.9% (STEP 1, 2.4 mg, 68 wks)

Head-to-head (SURMOUNT-5 NEJM 2025)

−20.2% at maximum tolerated dose

−13.7% at maximum tolerated dose; 47% less

GI tolerability (SURMOUNT-5)

Discontinuation 2.7%

Discontinuation 5.6% — worse GI tolerance at MTD

Weight rebound (after stopping)

SURMOUNT-4: +14% mean; >25% in most within 1yr

STEP 4/1 extension: ~2/3 weight returns in 1yr

Cardiovascular outcomes

SURPASS-CVOT ongoing; SUMMIT (HFpEF): positive

SELECT (NEJM 2023): HR 0.80; 20% MACE reduction; FDA CV indication 2024

HFpEF indication

SUMMIT trial: positive functional improvement

STEP-HFpEF (NEJM 2023): significant improvement

T2D head-to-head vs sema 1mg

SURPASS-2: superior HbA1c and WL

GLP-1 gold standard in T2D

MASH evidence

Phase 2 MASH (NEJM 2024): 54% resolution vs 35% placebo (12 wks)

ESSENCE: positive Phase 3 MASH data (sema 2.4mg)

Approval

Mounjaro (T2D 2022); Zepbound (obesity 2023); CV indication 2024

Ozempic (T2D 2017); Wegovy (obesity 2021); CV indication 2024

Compounded status 2026

Removed from shortage Dec 2024; compounding wind-down March 2025; legal challenges ongoing

Removed from shortage early 2025; same legal landscape

The honest clinical summary: tirzepatide produces more weight loss than semaglutide, with better GI tolerability at maximum doses. Semaglutide has the established cardiovascular outcomes evidence (SELECT). The patient for whom weight loss magnitude is the primary goal, who can access tirzepatide, and for whom the CV evidence gap while SURPASS-CVOT runs is acceptable — tirzepatide is the better choice. The patient with established CVD who needs the documented 20% MACE reduction — semaglutide's SELECT indication is the current evidence-based choice pending SURPASS-CVOT results. These are genuinely different clinical scenarios and the comparison deserves this nuance rather than a blanket winner/loser framing.

SURMOUNT-4 (JAMA 2023) and the post-hoc JAMA Internal Medicine analysis (February 2026) together provide the most current and comprehensive tirzepatide withdrawal data. The core finding: among participants who had achieved ≥10% weight reduction on 36 weeks of tirzepatide and then stopped, the mean weight regain was 14% over the subsequent 52 weeks. More importantly, the JAMA Int Med post-hoc analysis showed that >25% of initial weight loss was regained in most patients within 1 year — and those who regained the most weight had the greatest reversal of cardiometabolic benefits (HbA1c rose, blood pressure increased, lipids worsened proportionally to weight regained). The editorial accompanying the post-hoc analysis made the clinical point explicitly: 'There is a common misconception that patients can stop antiobesity medications when they reach their goal weight and maintain the weight that they lost and the cardiometabolic benefits they achieved.' The data contradicts this misconception directly.

For tirzepatide, the same chronic disease framing that applies to semaglutide is appropriate: this is a long-term or indefinite treatment for a chronic disease, not a weight loss course with a planned endpoint. Patients who stop tirzepatide after reaching goal weight should expect substantial weight regain within 1 year for most. The continuation arm of SURMOUNT-4 is equally important: participants who continued tirzepatide through week 88 achieved a total mean weight loss of 26% from study entry — demonstrating that the drug continues to produce weight loss benefit well beyond the 36-week initial period.

Tirzepatide was placed on the FDA drug shortage list due to extraordinary demand exceeding Lilly's manufacturing capacity. This allowed 503A and 503B compounding pharmacies to legally compound tirzepatide during the shortage. The FDA removed tirzepatide from the shortage list in December 2024, with compounders directed to wind down tirzepatide production by March 2025. The regulatory situation parallels the semaglutide compounding story — but with several differences. Unlike semaglutide (where some 503B outsourcing facilities challenged the shortage removal in court and maintained some operations), the tirzepatide wind-down was more abrupt. However, legal challenges from compounding pharmacy organizations were filed in early 2025, creating a contested regulatory environment through mid-2026.

Quality concerns documented for compounded tirzepatide: the FDA documented cases of compounded tirzepatide with incorrect potency, contamination, and — in some documented cases — completely different compounds than what was labeled. Independent assays of commercially available compounded tirzepatide showed similar potency variance (approximately 68-122%) as documented for compounded semaglutide. The specific safety risk for tirzepatide: the same dosing accuracy concern applies. At 15 mg labeled dose with 122% actual potency, a user receives approximately 18.3 mg — 22% above the Phase 3 maximum dose. At 68% potency, 15 mg labeled provides ~10.2 mg — enough to produce some effect but not the maximum efficacy. For a drug where GI side effects are dose-dependent and concentrated at escalation, undiscovered overdose from high-potency compounded product could produce severe GI events.

The GI adverse event profile for tirzepatide is consistent with the GLP-1 class. In SURMOUNT-1: nausea (29.7% at 15 mg vs 16.1% placebo), diarrhea (22.0% vs 11.7%), vomiting (9.8% vs 4.0%), constipation (15.9% vs 6.6%). The events were predominantly mild to moderate and concentrated during dose escalation. The notably lower GI discontinuation rate vs semaglutide in SURMOUNT-5 (2.7% vs 5.6%) suggests favorable tolerability at the population level despite the higher weight loss.

Tirzepatide carries the same GLP-1 agonist class black box warning for medullary thyroid carcinoma (MTC) — driven by rodent C-cell hyperplasia from GLP-1R activation on thyroid C-cells. The GIPR adds a question: does GIPR activation on thyroid C-cells contribute additional MTC risk? The current pharmacological evidence suggests GIPR expression on thyroid C-cells is lower than GLP-1R expression in rodents, and the MTC signal in tirzepatide rodent studies was consistent with the GLP-1R class effect rather than showing additive GIPR contribution. Human pharmacoepidemiological data across the large tirzepatide-exposed population has not shown elevated MTC incidence. Contraindications: personal or family history of MTC; MEN2.

Consistent with the GLP-1 class: pancreatitis risk not significantly elevated in the large SURMOUNT trials. Gallbladder events (cholelithiasis) at higher rates than placebo, consistent with rapid weight loss mechanism. Aspiration risk during anesthesia: same guidance as semaglutide — stop tirzepatide for the equivalent of 5 half-lives before elective procedures due to delayed gastric emptying (some practitioners use 4-week hold given tirzepatide's longer half-life vs semaglutide).

Similar to semaglutide: approximately 25-35% of weight loss comes from lean mass rather than fat mass in most tirzepatide studies. Resistance training and high-protein intake (1.2-1.6 g/kg/day) are the primary mitigation strategies. Studies combining tirzepatide with structured resistance training show substantially better fat/lean mass ratios than tirzepatide alone.

Semaglutide's SELECT trial (HR 0.80; 20% MACE reduction; n=17,604; 4 years) established that GLP-1R agonism produces cardiovascular benefit independent of weight loss in overweight/obese adults with established CVD and no T2D. Tirzepatide's cardiovascular outcomes trial, SURPASS-CVOT, is comparing tirzepatide against dulaglutide (a GLP-1 agonist control, not placebo) in patients with T2D and CVD. The trial design is important: it uses an active comparator (dulaglutide) rather than placebo — which tests whether tirzepatide is superior to an established GLP-1 agonist for CV outcomes, not whether it beats placebo. If SURPASS-CVOT shows superiority over dulaglutide, it confirms tirzepatide's CV benefit beyond GLP-1 agonism alone. If it shows non-inferiority, it confirms tirzepatide has at least the cardiovascular benefit of established GLP-1 agonists. Results are expected 2025-2026 and will be one of the most important data readouts in metabolic pharmacotherapy. The post-hoc analysis of SURMOUNT-5 CV risk score data (PMC12448458) showed significantly greater predicted 10-year CVD risk reduction with tirzepatide than semaglutide based on surrogate endpoints — but this is modeling, not outcomes data.

They are the same molecule (tirzepatide) from the same manufacturer (Eli Lilly), administered by the same route, using the same device, at the same doses. Mounjaro is the T2D brand; Zepbound is the obesity brand. Same drug, different indications, different insurance coverage. Using Mounjaro for weight loss when Zepbound is unavailable or not covered — pharmacologically identical outcome.

Not yet. Semaglutide has SELECT — a 4-year, n=17,604 cardiovascular outcomes trial showing 20% MACE reduction. Tirzepatide has SURPASS-CVOT, which is ongoing. The SUMMIT HFpEF trial showed functional benefit in heart failure. SURMOUNT-5 post-hoc analysis showed predicted CV risk reduction. None of this is the equivalent of SELECT's primary outcomes data. The cardiovascular outcomes gap between tirzepatide and semaglutide is real and clinically relevant for patients choosing between them for CV risk reduction specifically.

Efficacy magnitude is one dimension of drug choice. Semaglutide has established cardiovascular outcomes data (SELECT), lower cost in some markets, longer post-market safety surveillance, and equivalent rebound profile. For a patient with established CVD choosing between them, the SELECT data may outweigh the weight loss advantage until SURPASS-CVOT reports. For a patient without CVD whose primary goal is weight loss — tirzepatide's SURMOUNT-5 advantage is compelling.

SURMOUNT-5 was open-label — neither patients nor investigators were blinded to treatment assignment. This is acknowledged as a limitation by the investigators and commentators. For the primary endpoint of body weight change (an objective measure), open-label design has less impact than for subjective endpoints. For GI adverse events and discontinuation rates (subjective components), potential bias from unblinded reporting should be considered. The result is likely directionally correct — that tirzepatide produces more weight loss than semaglutide — but the specific magnitude of the advantage may have some systematic bias. The prior SURPASS-2 head-to-head in T2D (showing tirzepatide superiority in a similar design) is consistent with SURMOUNT-5's direction.

Will SURPASS-CVOT confirm that tirzepatide produces cardiovascular benefit (MACE reduction) equivalent to or greater than semaglutide's SELECT results? This is the single most important pending tirzepatide question.
What is the optimal maintenance dose for tirzepatide after weight loss is achieved? SURMOUNT-4 used maximum tolerated dose throughout. Whether a lower maintenance dose (e.g., 5 mg/week) can prevent the full rebound while reducing side effects and cost has not been studied.
Can slow tapering of tirzepatide (rather than abrupt discontinuation) reduce the weight rebound? The ECO 2024 tapering data for semaglutide showed some benefit; equivalent tirzepatide tapering studies are not yet published.
Does tirzepatide's GIP component produce benefits in MASH beyond what GLP-1 alone achieves? Phase 2 MASH data (Loomba 2024, NEJM) showed 54% MASH resolution; whether the GIP contribution adds meaningful benefit beyond semaglutide's MASH efficacy requires head-to-head MASH comparison.
What are the long-term (5-10 year) safety and efficacy data for tirzepatide? All pivotal SURMOUNT trials are 72-88 weeks. Long-term safety, including bone density, rare adverse events, and cardiovascular outcomes, requires longer follow-up.

Will SURPASS-CVOT confirm that tirzepatide produces cardiovascular benefit (MACE reduction) equivalent to or greater than semaglutide's SELECT results?

Why it matters · This is the single most important pending tirzepatide question.

What is the optimal maintenance dose for tirzepatide after weight loss is achieved?

Why it matters · SURMOUNT-4 used maximum tolerated dose throughout. Whether a lower maintenance dose (e.g., 5 mg/week) can prevent the full rebound while reducing side effects and cost has not been studied.

Can slow tapering of tirzepatide (rather than abrupt discontinuation) reduce the weight rebound?

Why it matters · The ECO 2024 tapering data for semaglutide showed some benefit; equivalent tirzepatide tapering studies are not yet published.

Does tirzepatide's GIP component produce benefits in MASH beyond what GLP-1 alone achieves?

Why it matters · Phase 2 MASH data (Loomba 2024, NEJM) showed 54% MASH resolution; whether the GIP contribution adds meaningful benefit beyond semaglutide's MASH efficacy requires head-to-head MASH comparison.

What are the long-term (5-10 year) safety and efficacy data for tirzepatide?

Why it matters · All pivotal SURMOUNT trials are 72-88 weeks. Long-term safety, including bone density, rare adverse events, and cardiovascular outcomes, requires longer follow-up.

[1]
Jastreboff AM, et al (2022)
Tirzepatide Once Weekly for the Treatment of Obesity
NEJM
PMID: 35658024 Review
[2]
Aronne LJ, et al (2023)
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity
JAMA
ReviewNeeds link
[3]
Horn DB, Linetzky B, Davies MJ, et al (2026)
Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal
JAMA Internal Medicine
DOI: 10.1001/jamainternmed.2025.6112 Review
[4]
Aronne LJ, et al (2025)
Tirzepatide versus Semaglutide for Obesity
New England Journal of Medicine
ReviewNeeds link
[5]
Frías JP, et al (2021)
Tirzepatide versus Semaglutide Once Weekly in Patients with T2D
NEJM
ReviewNeeds link
[6]
Packer M, et al (2024)
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
NEJM
ReviewNeeds link

Jastreboff AM, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. NEJM. 387:205-216. PMID 35658024. [SURMOUNT-1: n=2,539; 72 weeks; -22.5% WL at 15 mg vs -2.4% placebo; 57% ≥20% WL; the foundational obesity efficacy paper.]

Aronne LJ, et al. (2023). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity. JAMA. 330:2247-2256. [SURMOUNT-4: discontinuation → +14% regain in 52 weeks; continuation → -26% total weight loss; the maintenance and rebound paper.]

Horn DB, Linetzky B, Davies MJ, et al. (2026) [3]. Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal. JAMA Internal Medicine. 186(2):157-167. doi:10.1001/jamainternmed.2025.6112. [SURMOUNT-4 post-hoc; >25% regain in most within 1 year; cardiometabolic benefits reversed proportional to regain; Feb 2026 publication.]

Aronne LJ, et al. (2025). Tirzepatide versus Semaglutide for Obesity. New England Journal of Medicine. NCT05822830. [SURMOUNT-5: n=751; 72 weeks; tirzepatide -20.2% vs semaglutide -13.7% (47% greater); GI DC 2.7% vs 5.6%; waist circumference -18.4 vs -13.0 cm; the definitive head-to-head.]

Frías JP, et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with T2D. NEJM. 385:503. [SURPASS-2: head-to-head T2D; tirzepatide superior for HbA1c and WL; Grade A.]

Packer M, et al. (2024). Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. NEJM. [SUMMIT trial; HFpEF functional improvement; first pharmacotherapy showing KCCQ and 6MWT improvement in HFpEF.]

Decision framework

Primary goal = maximum weight loss (approved drug): tirzepatide is the current best option; SURMOUNT-5 head-to-head confirms superiority over semaglutide.
Primary goal = cardiovascular risk reduction with established CVD: semaglutide (Wegovy/Ozempic) has SELECT evidence (HR 0.80; 20% MACE reduction); tirzepatide SURPASS-CVOT results pending; semaglutide is the current evidence-based choice for this specific indication.
T2D + weight management: tirzepatide (Mounjaro) is superior to semaglutide (Ozempic) for both HbA1c reduction and weight loss in the SURPASS-2 head-to-head.
HFpEF + obesity: SUMMIT trial supports tirzepatide for functional improvement in HFpEF.
Treatment duration: chronic disease management framing mandatory; SURMOUNT-4 confirms weight and cardiometabolic benefit returns when drug stops; plan for long-term treatment.
Muscle preservation: resistance training + protein 1.2-1.6 g/kg/day essential throughout treatment.
Compounded tirzepatide (2026): FDA shortage status removed December 2024; legal compounding pathway complex; quality issues documented; branded pharmaceutical preferred when accessible.

— End of Tirzepatide —

THE PEPTIDE BIBLE | Tirzepatide | For Research & Educational Purposes Only

Chapter Summary

Tirzepatide: 39-amino acid synthetic peptide; dual GIPR + GLP-1R agonist; C20 fatty diacid lipidation; once-weekly SubQ. Eli Lilly. FDA-APPROVED: Mounjaro (T2D, May 2022); Zepbound (obesity Nov 2023; CV risk reduction 2024). Mounjaro and Zepbound = same molecule, different indication/label. Six dose levels: 2.5/5/7.5/10/12.5/15 mg weekly. MECHANISM: GLP-1R (appetite suppression, glucose-dependent insulin, glucagon suppression, gastric slowing) + GIPR (adipose tissue energy expenditure, CNS appetite suppression via distinct hypothalamic circuits, beta cell preservation, body composition — visceral fat preferentially reduced). GIP + GLP-1 synergy hypothesis: dual receptor engagement amplifies appetite suppression beyond additive. GIP receptor rehabilitation: historically considered impaired/unhelpful in T2D; tirzepatide revealed pharmacological GIPR agonism benefits at adipose and CNS level even when incretin response attenuated. SURMOUNT-1 (NEJM 2022; Jastreboff): n=2,539; 72wks; 15mg: -22.5% vs -2.4% placebo; 57% ≥20% WL; 91% ≥5% WL; Grade A. SURMOUNT-4 (JAMA 2023): withdrawal after 36wks → +14% mean regain in 52wks; continuation → -26% total from study start. JAMA Int Med 2026 post-hoc: >25% regain in most within 1yr; CV benefits reversed proportionally. SURMOUNT-5 (NEJM 2025; Aronne): NCT05822830; n=751; 72wks; open-label; tirzepatide -20.2% vs semaglutide -13.7% at MTD; 47% greater RWL; waist -18.4 vs -13.0 cm; GI DC 2.7% vs 5.6% (better tolerability); 5 secondary endpoints met; Grade A. SURPASS-2 (NEJM 2021): T2D head-to-head vs sema 1mg; tirzepatide -2.46% HbA1c vs -1.86%; WL -12.7 vs -6.2 kg; Grade A. SUMMIT (NEJM 2024): HFpEF + obesity; KCCQ + 6MWT significant improvement; first pharmacotherapy for HFpEF functional outcomes. SURPASS-CVOT: CV outcomes vs dulaglutide; ongoing; results expected 2025-2026. vs SEMAGLUTIDE: superior WL (SURMOUNT-5); better GI tolerability at MTD; pending CV outcomes (sema has SELECT HR 0.80). SAFETY: GI AEs (nausea 29.7%, diarrhea 22.0%, vomiting 9.8% at 15mg — class-consistent); MTC black box (GLP-1R + GIPR C-cell question; no elevated human MTC signal); pancreatitis not elevated; gallbladder events (rapid WL mechanism); aspiration risk — hold 4 weeks before elective procedures; lean mass loss 25-35% of WL — protein + resistance training essential. COMPOUNDED: FDA shortage removed Dec 2024; wind-down March 2025; quality issues documented; not WADA banned.